Remarkably, a high frequency of ERCC2 (32%) mutations was detected as noted recently [26] that have been found to be associated with an improved response to platinum chemotherapy in advanced urothelial carcinoma [41]. The gene discussed is ERCC2; the disease is urothelial carcinoma.